Search Results for ""drugs for""
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for "drugs for". Results 2541 to 2550 of 2680 total matches.

PPIs and Fracture Risk

   
The Medical Letter on Drugs and Therapeutics • Feb 18, 2013  (Issue 1410)
The Medical Letter® On Drugs and Therapeutics Volume 55 (Issue 1410) February 18, 2013 ...
Use of proton pump inhibitors (PPIs) to treat gastroesophageal reflux disease (GERD) has been associated with an increase in the risk of fractures. The FDA now requires that the labels of all prescription PPIs include a warning about an increased risk of fractures with long-term use.
Med Lett Drugs Ther. 2013 Feb 18;55(1410):15-6 |  Show IntroductionHide Introduction

Mumps Outbreak

   
The Medical Letter on Drugs and Therapeutics • Mar 17, 2014  (Issue 1438)
The Medical Letter® On Drugs and Therapeutics Published by The Medical Letter, Inc. • 145 ...
An outbreak of mumps has occurred among students at Fordham University in New York. All of those who developed mumps had been vaccinated against the disease.
Med Lett Drugs Ther. 2014 Mar 17;56(1438):21 |  Show IntroductionHide Introduction

In Brief: Acalabrutinib (Calquence) for Mantle Cell Lymphoma (online only)

   
The Medical Letter on Drugs and Therapeutics • Nov 05, 2018  (Issue 1559)
. www.fdbhealth.com/policies/drug-pricing-policy. acalabrutinib Calquence ibrutinib Imbruvica lymphoma ...
The FDA has approved the Bruton tyrosine kinase (BTK) inhibitor acalabrutinib (Calquence – AstraZeneca) for oral treatment of relapsed or refractory mantle cell lymphoma. Acalabrutinib is the second BTK inhibitor to be approved for this indication; ibrutinib (Imbruvica) was approved in 2013.Ibrutinib inhibits other kinases in addition to BTK and has been associated with severe adverse effects, particularly atrial fibrillation, infection, rash, and bleeding, that may be related to inhibition of kinases other than BTK.1 Acalabrutinib is a more selective BTK inhibitor than ibrutinib; whether...
Med Lett Drugs Ther. 2018 Nov 5;60(1559):e184 |  Show IntroductionHide Introduction

In Brief: Brentuximab Vedotin (Adcetris) for Classical Hodgkin's Lymphoma (online only)

   
The Medical Letter on Drugs and Therapeutics • Nov 05, 2018  (Issue 1559)
the anti-CD30 antibody-drug conjugate brentuximab vedotin (Adcetris – Seattle Genetics) for use ...
The FDA has approved the anti-CD30 antibody-drug conjugate brentuximab vedotin (Adcetris – Seattle Genetics) for use in combination with chemotherapy for IV treatment of adults with previously untreated stage 3 or 4 classical Hodgkin's lymphoma (cHL). Adcetris was approved earlier for consolidation treatment of cHL and for treatment of relapsed or refractory cHL, anaplastic large cell lymphoma, and CD30-expressing mycosis fungoides.FDA approval for the new indication was based on the results of an open-label trial (ECHELON-1) in 1334 patients with previously untreated stage 3 or 4 cHL.1...
Med Lett Drugs Ther. 2018 Nov 5;60(1559):e185 |  Show IntroductionHide Introduction

In Brief: Pfizer/BioNTech COVID-19 Vaccine Authorized for Adolescents 12-15 Years Old

   
The Medical Letter on Drugs and Therapeutics • May 31, 2021  (Issue 1625)
May 11, 2021. 2. FDA authorizes Pfizer-BioNTech COVID-19 vaccine. Med Lett Drugs Ther 2021; 63:1. 3 ...
On May 10, 2021, the FDA expanded its Emergency Use Authorization (EUA) for the Pfizer/BioNTech mRNA-based COVID-19 vaccine to include adolescents 12-15 years old.1The vaccine has been authorized for use in persons ≥16 years old since December 2020.
Med Lett Drugs Ther. 2021 May 31;63(1625):81 |  Show IntroductionHide Introduction

In Brief: Guillain-Barré Syndrome with the Johnson & Johnson COVID-19 Vaccine

   
The Medical Letter on Drugs and Therapeutics • Aug 09, 2021  (Issue 1630)
vaccination. Ann Neurol 2021 June 10 (epub). COVID-19 vaccines drug safety ...
On July 12, 2021, the FDA added a warning to the Fact Sheet for the Johnson & Johnson (Janssen) adenovirus-based COVID-19 vaccine about an increased risk of Guillain-Barré syndrome (GBS) following administration of the product.
Med Lett Drugs Ther. 2021 Aug 9;63(1630):121 |  Show IntroductionHide Introduction

In Brief: Primary Aldosteronism Screening in Patients with Hypertension

   
The Medical Letter on Drugs and Therapeutics • Nov 10, 2025  (Issue 1741)
continuing most other antihypertensive drugs during screening.2 TREATMENT — Targeted treatment of primary ...
Recently published guidelines recommend screening patients with hypertension for primary aldosteronism. The Endocrine Society recommends screening all patients and the American College of Cardiology/American Heart Association (ACC/AHA) recommend screening those at increased risk (see Table 1).
Med Lett Drugs Ther. 2025 Nov 10;67(1741):184   doi:10.58347/tml.2025.1741e |  Show IntroductionHide Introduction

Varicella Vaccine

   
The Medical Letter on Drugs and Therapeutics • Jun 23, 1995  (Issue 951)
The Medical Letter  On Drugs and Therapeutics www.medletter.com Published by The Medical ...
A live attenuated varicella vaccine (Varivax - Merck) has been approved for marketing by the US Food and Drug Administration. The Oka/Merck strain used in the vaccine is attenuated by passage in human and embryonic guinea pig cell cultures.
Med Lett Drugs Ther. 1995 Jun 23;37(951):55-7 |  Show IntroductionHide Introduction

Pegylated Interferon (PEG-Intron) for Chronic Hepatitis C

   
The Medical Letter on Drugs and Therapeutics • Jun 25, 2001  (Issue 1107)
The Medical Letter  On Drugs and Therapeutics www.medletter.com Published by The Medical ...
Recombinant interferon alfa-2b conjugated to polyethylene glycol (PEG-Intron), the first "pegylated"alpha interferon, has been approved by the FDA for once-a-week monotherapy of chronic hepatitis C virus (HCV) infection in patients not previously treated with alpha interferon.
Med Lett Drugs Ther. 2001 Jun 25;43(1107):54-5 |  Show IntroductionHide Introduction

Echinacea for Prevention and Treatment of Upper Respiratory Infections

   
The Medical Letter on Drugs and Therapeutics • Apr 01, 2002  (Issue 1127)
The Medical Letter  On Drugs and Therapeutics www.medletter.com Published by The Medical ...
Echinacea, a plant also called purple coneflower, is widely used as a dietary supplement for prevention and treatment of colds.
Med Lett Drugs Ther. 2002 Apr 1;44(1127):29-30 |  Show IntroductionHide Introduction